Galmed Pharmaceuticals Ltd., a prominent entity in the biopharmaceutical sector, has been actively engaged in the development and commercialization of innovative treatments targeting liver diseases and cholesterol gallstones. As a company operating within the health care sector, Galmed Pharmaceuticals is a key player in the biotechnology industry, focusing on addressing critical medical needs through its specialized product offerings.
The company’s financial metrics as of April 7, 2026, reflect a close price of $0.6224, with a 52-week high recorded at $2.68 on April 27, 2025, and a 52-week low of $0.411 on March 26, 2026. These figures indicate the stock’s volatility over the past year. Galmed Pharmaceuticals holds a market capitalization of approximately $3,883,020 USD, underscoring its position within the market. The price-to-earnings ratio stands at -0.24, suggesting that the company is currently not generating profits.
Galmed Pharmaceuticals Ltd. was established with a mission to innovate within the realm of liver disease and cholesterol gallstone treatments. The company’s strategic focus on these areas highlights its commitment to addressing significant health challenges. By offering its products to the healthcare and medical industries, Galmed Pharmaceuticals aims to improve patient outcomes and enhance the quality of life for individuals suffering from these conditions.
The company’s presence on the Nasdaq stock exchange, where it went public on March 13, 2014, has provided it with a platform to access capital and expand its research and development efforts. This public listing has been instrumental in facilitating the company’s growth and enabling it to pursue its strategic objectives in the competitive biotechnology landscape.
For further information, stakeholders and interested parties can visit Galmed Pharmaceuticals’ official website at www.galmedpharma.com , where updates on the company’s progress, research initiatives, and product developments are regularly posted. Through its continued focus on innovation and patient care, Galmed Pharmaceuticals Ltd. remains dedicated to advancing the field of biopharmaceuticals and contributing to the broader health care sector.
